Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of LXE408 in Healthy Subjects
NCT07809919Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LXE408 in visceral leishmaniasis (VL) and Chagas disease (11 cohorts), sponsored by Novartis. Primary endpoint: Number of participants with Adverse Events at 63 days. Started Dec 2018; status: completed.
02
Drugs
LXE408
03
Conditions
visceral leishmaniasis (VL)Chagas disease
Beyond the preview
Go deeper on NCT07809919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809919.